- The Wall Street Journal•7 days ago
Valeant Pharmaceuticals International shareholders just can’t catch a break. Shares in the beleaguered drug maker fell nearly 7% Friday after Valeant announced that the Food and Drug Administration has ...
- Reuters•2 years ago
French pharmaceutical firm Nicox said it had notified Bausch + Lomb, a division of Valeant Pharmaceuticals, that it would exercise its option to co-promote eye drug latanoprostene bunod in the United States. ...
|Bid||10.65 x 168100|
|Ask||10.85 x 50000|
|52wk Range||1.55 - 13.68|
|Day's Range||9.62 - 10.43|
|Avg Vol (3m)||360,666|
As of 11:37 AM EDT. Market closed.